Randomized Double-blind Efficacy and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-na ve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

  • STATUS
    Recruiting
  • End date
    Jan 1, 2025
  • participants needed
    680
  • sponsor
    Merck Sharp & Dohme Corp.
Updated on 21 July 2021

Summary

This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL [also known as MK-8591A]) in treatment-nave participants with human immunodeficiency virus type-1 (HIV-1) infection. The primary objectives are to evaluate the antiretroviral activity, safety, and tolerability of DOR/ISL compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that DOR/ISL is noninferior or superior to BIC/FTC/TAF treatment based on the percentage of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48.

Details
Condition HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection, HIV-1 Infection
Treatment DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Clinical Study IdentifierNCT04233879
SponsorMerck Sharp & Dohme Corp.
Last Modified on21 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is HIV-1 positive
Is nave to antiretroviral therapy (ART) defined as having received 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection including prevention of mother-to-child transmission up to 1 month prior to screening
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) Is not a woman of childbearing potential (WOCBP); 2) Is a WOCBP and using an acceptable contraceptive method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis); 3) A WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) within 24 hours before the first dose of study intervention; 4) If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required

Exclusion Criteria

Has HIV-2 infection
Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator
Has an active diagnosis of hepatitis due to any cause, including active HBV infection (defined as hepatitis B surface antigen [HBsAg]-positive or hepatitis B virus deoxyribonucleic acid [HBV DNA]-positive)
Has a history of malignancy 5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study
Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1
Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapy from 45 days prior to Day 1 through the study intervention period
Is currently participating in or has participated in a clinical study with an investigational compound or device from 45 days prior to Day 1 through the study intervention period
Has a documented or known virologic resistance to any approved HIV-1 reverse transcriptase inhibitor, or any study intervention
Has exclusionary laboratory values within 45 days prior to Day 1
Is female and is expecting to conceive or donate eggs at any time during the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note